Findings from Two-Year Pivotal Phase III TEMSO Trial
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).
Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Gilead Sciences, Inc. (Nasdaq: GILD) have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV.
Pfizer Announces Licensing Agreement With Puma Biotechnology
- Details
- Category: Pfizer
Pfizer Inc. announced an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer.
Abbott Enrolls First U.S. Patient in Global EXCEL Trial
- Details
- Category: Abbott
Abbott has begun enrolling U.S. patients in the EXCEL (Evaluation of XIENCE PRIME™ or XIENCE V® versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial.
Merck and Ono Pharmaceutical Form Collaborations
- Details
- Category: Merck Group
Merck KGaA announced that it signed two agreements for collaboration of its Merck Serono division with Ono Pharmaceutical Co., Ltd., Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.
BRILIQUE receives a positive preliminary medical benefit assessment
- Details
- Category: AstraZeneca
AstraZeneca today announced that the German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality and Efficiency in Healthcare (IQWiG) preliminary assessment report regarding the medical benefit of BRILIQUE (ticagrelor).
Merck Publishes 2010 Global Corporate Responsibility Report
- Details
- Category: Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, launched its 2010 global corporate responsibility report, which emphasizes the importance of discovering better ways of doing business to benefit both society and its business.
More Pharma News ...
- Takeda completes acquisition and names new CEO of Nycomed
- NABP and Pfizer Partner to Educate Patients About The Flood of Counterfeit Medicines Online
- Lilly Launches Open Innovation Drug Discovery Platform
- Merck publishes innovation brochure with interactive features
- Sanofi successfully prices USD 1 billion bond issue
- New Novartis data show potential of respiratory portfolio
- Roche's investigational medicine T-DM1 shows improvement in progression-free survival